1. In patients with advanced, platinum-resistant ovarian cancer, combination therapy of a tyrosine kinase inhibitor, pazopanib, with paclitaxel significantly increased progression-free survival compared to paclitaxel alone.
2. Patients who received pazopanib plus paclitaxel suffered from higher rates of serious side effects including neutropenia, leucopenia, and hypertension.
Evidence Rating Level: 2 (Good)